Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Tennessee Imaavy Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield of TennesseePolicy ID_CHS_69842026a_1126

    Nipocalimab-aahu (Imaavy) Coverage Criteria

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_69842026a_1126 alerts

    Get alerted when Policy ID_CHS_69842026a_1126 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization, step therapy, and continued coverage criteria for nipocalimab-aahu (Imaavy) in eligible members with generalized myasthenia gravis or warm autoimmune hemolytic anemia.

    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyNipocalimab-aahu (Imaavy) Coverage Criteria
    Policy CodePolicy ID_CHS_69842026a_1126
    Change TypeNo material change
    Effective DateJanuary 30, 2027
    Next Review DateN/A
    Key ActionConsult the Step Therapy Requirements for Provider Administered Specialty Medications document before submitting authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2FDA-approved covered indications
    12 monthsInitial authorization
    12 monthsContinuation authorization
    MGFA II-IVgMG classification
    MG-ADL ≥5

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    gMG disease burden
    ≥3 monthswAIHA diagnosis duration

    Covered Indications and Exclusions

    Initial Therapy — Generalized Myasthenia Gravis

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Member is an adult or pediatric patient 12 years of age or older with generalized myasthenia gravis (gMG) and is positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.
    • Myasthenia Gravis Foundation of America (MGFA) clinical classification is II to IV.
    • MG activities of daily living (MG-ADL) total score is greater than or equal to 5.>= 5
    • ONE of the following

      • Member has had an inadequate response or intolerable adverse event to at least two immunosuppressive therapies over the course of at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate, or tacrolimus).
      • Member has had an inadequate response or intolerable adverse event to at least one immunosuppressive therapy and intravenous immunoglobulin (IVIG) over the course of at least 12 months.
      • Member has a documented clinical reason to avoid therapy with immunosuppressive agents and IVIG.
    • The requested medication will not be used in combination with another neonatal Fc receptor blocker (e.g., Rystiggo, Vyvgart, or Vyvgart Hytrulo), complement inhibitor (e.g., Soliris, Ultomiris, or Zilbrysq), or Uplizna.

    Initial Therapy — Warm Autoimmune Hemolytic Anemia

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Member is an adult or pediatric patient 12 years of age or older with a diagnosis of warm autoimmune hemolytic anemia (wAIHA) for at least 3 months.>= 3 months
    • Hemoglobin is less than 10 g/dL.< 10 g/dL
    • Evidence of hemolysis confirmed by ONE of the following

      • Lactic dehydrogenase (LDH) is above the upper limit of normal.
      • Indirect bilirubin is above the upper limit of normal.

    Continuation Therapy — Generalized Myasthenia Gravis

    Covered when ALL of the following continuation criteria are met:

    ALL of the following

    • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Member demonstrates a positive response to therapy (e.g., improvement in MG-ADL score, MG Manual Muscle Test [MMT], or MG Composite).
    • The requested medication will not be used in combination with another neonatal Fc receptor blocker (e.g., Rystiggo, Vyvgart, or Vyvgart Hytrulo), complement inhibitor (e.g., Soliris, Ultomiris, or Zilbrysq), or Uplizna.

    Continuation Therapy — Warm Autoimmune Hemolytic Anemia

    Covered when ALL of the following continuation criteria are met:

    ALL of the following

    • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Member demonstrates a positive response to therapy (e.g., improvement in hemoglobin levels, improvement in markers of hemolysis, or improvement in fatigue).

    Imaavy is covered for the FDA-approved indications of generalized myasthenia gravis (gMG) and warm autoimmune hemolytic anemia (wAIHA) when the applicable criteria are met. Use for all other indications is considered experimental/investigational and not medically necessary.

    Coverage excludes cold antibody autoimmune hemolytic anemia (AIHA), cold agglutinin syndrome, mixed type (warm and cold) AIHA, and paroxysmal cold hemoglobinuria.

    Imaavy must not be used concurrently with another neonatal Fc receptor blocker (e.g., Rystiggo, Vyvgart, or Vyvgart Hytrulo), a complement inhibitor (e.g., Soliris, Ultomiris, or Zilbrysq), or Uplizna.

    Clinical Thresholds and Authorization Terms

    MG-ADL score
    Required scoreMG-ADL total score ≥5
    Initial useRequired for initial generalized myasthenia gravis (gMG) authorization
    Continuation responseImprovement in MG-ADL score may support a positive response for continued gMG treatment
    Hemoglobin
    Required hemoglobin<10 g/dL
    Applies toInitial warm autoimmune hemolytic anemia (wAIHA) authorization
    Related findingMust be accompanied by qualifying evidence of hemolysis

    Authorization and Documentation Requirements

    Step Therapy

    Step Therapy Required

    Step therapy is required before authorization. Providers must consult the applicable provider-administered specialty medication step therapy requirements.

    • See the separate Step Therapy Requirements for Provider Administered Specialty Medications document: https://www.bcbst.com/docs/providers/Comm_BC_PAD_Step_Therapy_Guide.pdf
    Documentation Required

    Clinical Records Required

    Submit the clinical records needed to initiate prior authorization and support reauthorization. Initial requests require chart notes, medical records, or claims history; continuation requests require documentation supporting a positive clinical response.

    • Initial requests: provide chart notes, medical records, or claims history documenting the applicable diagnosis, clinical findings, prior treatment history, and response or reasons therapy was avoided.
    • Continuation requests: provide chart notes or medical records supporting positive clinical response.

    Policy Background

    Nipocalimab-aahu (Imaavy) is covered for eligible adult and pediatric members 12 years of age and older with antibody-positive generalized myasthenia gravis or with warm autoimmune hemolytic anemia who are currently or previously treated with corticosteroids. Coverage is subject to the applicable clinical criteria, treatment history, documentation, and exclusion requirements.

    Clinical Definitions

    Generalized myasthenia gravis (gMG)
    PopulationAdult and pediatric patients 12 years of age and older
    Antibody statusPositive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies
    Clinical scopeGeneralized myasthenia gravis; initial authorization also requires MGFA clinical classification II to IV and MG-ADL score ≥5
    Warm autoimmune hemolytic anemia (wAIHA)
    PopulationAdult and pediatric patients 12 years of age and older
    Diagnostic scopeWarm autoimmune hemolytic anemia supported by anemia and evidence of hemolysis

    Initial Authorization

    gMG Initial Authorization

    Authorization of 12 months may be granted when ALL of the following generalized myasthenia gravis criteria are met:

    gMG initial authorization

    • Positive anti-AChR or anti-MuSK antibody testing; MGFA clinical classification II to IV; and MG-ADL total score of at least 5.MGFA II-IV; MG-ADL ≥5
    • ONE prior-treatment or avoidance pathway

      • Inadequate response or intolerable adverse event to at least two immunosuppressive therapies over at least 12 months.
      • Inadequate response or intolerable adverse event to at least one immunosuppressive therapy and IVIG over at least 12 months.

    Continued Authorization

    gMG Continuation Authorization

    Authorization of 12 months may be granted for continued treatment when ALL of the following generalized myasthenia gravis criteria are met:

    gMG continuation authorization

    • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • The member demonstrates a positive response to therapy.

      Examples include improvement in MG-ADL score, MG Manual Muscle Test (MMT), or MG Composite.

    • The requested medication will not be used in combination with another neonatal Fc receptor blocker, complement inhibitor, or Uplizna.

    wAIHA Continuation Authorization

    Authorization of 12 months may be granted for continued treatment when ALL of the following warm autoimmune hemolytic anemia criteria are met:

    Required Prior Treatment

    StepRequirement
    1Step therapy is required. Consult the Step Therapy Requirements for Provider Administered Specialty Medications document for the applicable requirements.
    StepIndicationRequirement
    2Generalized myasthenia gravis (gMG)The member must have failed or been unable to tolerate at least two immunosuppressive therapies over at least 12 months, or at least one immunosuppressive therapy plus intravenous immunoglobulin (IVIG) over at least 12 months. A documented clinical reason to avoid immunosuppressive agents and IVIG may be used as an alternative pathway.
    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyNipocalimab-aahu (Imaavy) Coverage Criteria
    Policy CodePolicy ID_CHS_69842026a_1126
    Change TypeNo material change
    Effective DateJanuary 30, 2027
    Next Review DateN/A
    Key ActionConsult the Step Therapy Requirements for Provider Administered Specialty Medications document before submitting authorization.
    SourceLink
    On This Page
    Covered Indications and ExclusionsClinical Thresholds and Authorization TermsAuthorization and Documentation RequirementsPolicy BackgroundClinical DefinitionsInitial AuthorizationContinued AuthorizationRequired Prior Treatment
  1. Haptoglobin is below the lower limit of normal.
  2. Direct antiglobulin test (DAT) is positive for immunoglobulin G (IgG), with or without complement component 3d (C3d).
  3. Member is currently receiving treatment for wAIHA or has previously received treatment for wAIHA (e.g., corticosteroids, rituximab, azathioprine, mycophenolate mofetil, or methotrexate).
  4. Member has not been diagnosed with cold antibody autoimmune hemolytic anemia (AIHA), cold agglutinin syndrome, mixed type (warm and cold) AIHA, or paroxysmal cold hemoglobinuria.
  5. wAIHA diagnosis duration
    Required durationwAIHA diagnosis for at least 3 months
    Diagnostic supportDiagnosis must be confirmed by hemoglobin <10 g/dL and qualifying evidence of hemolysis
    Treatment historyMember must be currently receiving or have previously received treatment for wAIHA
    Authorization duration
    Initial gMG authorization12 months
    Initial wAIHA authorization12 months
    Continued gMG authorization12 months
    Continued wAIHA authorization12 months
    Documentation Required

    gMG Documentation

    For gMG, submit documentation of all required disease-specific findings and treatment history.

    • Positive anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody test.
    • Myasthenia Gravis Foundation of America (MGFA) clinical classification; authorization criteria require class II to IV.
    • MG activities of daily living (MG-ADL) total score of at least 5.
    • Previous medications tried, including response to therapy; if therapy is not advisable, document the clinical reasons to avoid it.
    • For authorization, document inadequate response or intolerable adverse events to at least two immunosuppressive therapies over at least 12 months, or to at least one immunosuppressive therapy and IVIG over at least 12 months, unless there is a documented clinical reason to avoid immunosuppressive agents and IVIG.
    Documentation Required

    wAIHA Documentation

    For wAIHA, submit documentation confirming the diagnosis, qualifying hemolysis, and treatment history.

    • Document wAIHA for at least 3 months in patients age 12 years and older.
    • Hemoglobin <10 g/dL.
    • Evidence of hemolysis: LDH above the upper limit of normal, indirect bilirubin above the upper limit of normal, haptoglobin below the lower limit of normal, or a direct antiglobulin test (DAT) positive for IgG with or without C3d.
    • Document current or previous wAIHA treatment, including corticosteroids or other therapies such as rituximab, azathioprine, mycophenolate mofetil, or methotrexate.

    Unsupported block type: prior_auth

    Denial Risk

    Noncovered Indications

    Requests for indications other than the FDA-approved uses are not medically necessary. Imaavy is FDA-approved for gMG and wAIHA in adult and pediatric patients 12 years of age and older meeting the applicable criteria.

    • gMG: patients who are anti-AChR or anti-MuSK antibody positive.
    • wAIHA: patients currently or previously treated with corticosteroids.
    • All other indications are considered experimental/investigational and not medically necessary.
    Denial Risk

    Prohibited Combination Therapy

    Do not use the requested medication concurrently with another neonatal Fc receptor blocker, complement inhibitor, or Uplizna. This restriction applies to both initial authorization and reauthorization.

    • Neonatal Fc receptor blockers include Rystiggo, Vyvgart, and Vyvgart Hytrulo.
    • Complement inhibitors include Soliris, Ultomiris, and Zilbrysq.
    • Concurrent use with Uplizna is also prohibited.
    Denial Risk

    Excluded Hemolytic Anemia Diagnoses

    wAIHA requests are not eligible when the member has any of the following excluded hemolytic anemia diagnoses.

    • Cold antibody autoimmune hemolytic anemia (AIHA).
    • Cold agglutinin syndrome.
    • Mixed type AIHA, including warm and cold AIHA.
    • Paroxysmal cold hemoglobinuria.
    Denial Risk

    Continuation Criteria and Denial Risks

    Reauthorization may be denied when continuation criteria are not met. Documentation must show that the member continues to benefit from therapy without unacceptable toxicity or disease progression.

    • Unacceptable toxicity or disease progression on the current regimen is a denial condition.
    • Absence of a positive clinical response is a denial condition.
    • For gMG, positive response may include improvement in MG-ADL score, MG Manual Muscle Test (MMT), or MG Composite.
    • For wAIHA, positive response may include improvement in hemoglobin levels, markers of hemolysis, or fatigue.
    Treatment status
    Member must be currently or previously treated with corticosteroids; current or prior wAIHA treatment is required for authorization
    Excluded diagnosesCold antibody AIHA, cold agglutinin syndrome, mixed warm and cold AIHA, and paroxysmal cold hemoglobinuria are excluded
    MG-ADL
    DefinitionMyasthenia Gravis activities of daily living (MG-ADL) score
    RoleUsed to document gMG disease burden
    Initial authorization thresholdTotal score ≥5
    Continuation responseImprovement in MG-ADL score may demonstrate a positive response to therapy
    MGFA clinical classification
    DefinitionMyasthenia Gravis Foundation of America (MGFA) clinical classification
    Required rangeClass II to IV
    Authorization roleRequired for initial gMG authorization
    A documented clinical reason to avoid therapy with immunosuppressive agents and IVIG.
  6. The requested medication will not be used in combination with another neonatal Fc receptor blocker, complement inhibitor, or Uplizna.
  7. wAIHA Initial Authorization

    Authorization of 12 months may be granted when ALL of the following warm autoimmune hemolytic anemia criteria are met:

    wAIHA initial authorization

    • The member has a wAIHA diagnosis for at least 3 months and hemoglobin below 10 g/dL.Diagnosis ≥3 months; hemoglobin <10 g/dL
    • ONE qualifying hemolysis finding

      • LDH is above the upper limit of normal.
      • Indirect bilirubin is above the upper limit of normal.
      • Haptoglobin is below the lower limit of normal.
      • DAT is positive for IgG with or without C3d.
    • The member is currently receiving or has previously received treatment for wAIHA.
    • The member has not been diagnosed with cold antibody AIHA, cold agglutinin syndrome, mixed-type warm and cold AIHA, or paroxysmal cold hemoglobinuria.

    wAIHA continuation authorization

    • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • The member demonstrates a positive response to therapy.

      Examples include improvement in hemoglobin levels, improvement in markers of hemolysis, or improvement in fatigue.